WILMINGTON, Delaware, May 22 -- AstraZeneca, a biopharmaceutical company, issued the following news release on May 21, 2025: * * * AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, Ma more PR

WILMINGTON, Delaware, May 23 -- DuPont issued the following news release: * * * DuPont Expands Bioprocessing Portfolio with Launch of DuPont (TM) AmberChrom(TM) TQ1 Chromatography Resin Agarose-based chromatography resin supports purification of oligonucleotides and peptides for biopharma applications WILMINGTON, Del., May 22, 2025, - DuPont has expanded its bioprocessing portfolio with the launch of DuPont(TM) AmberChrom(TM) TQ1 chromatography resin for the purification of oligonucleotides more PR

HOUSTON, Texas, May 20 -- Hines, a real estate investment manager, issued the following news release on May 19 2025: * * * Hines Private Wealth Solutions Successfully Completes $194 Million DST DST offering was designed with investors' wealth preservation and estate planning needs in mind (HOUSTON)--Hines, the global real estate investor, developer and manager announced today that Hines Private Wealth Solutions LLC has successfully completed another Delaware Statutory Trust ("DST") with HREX more PR

HARRISBURG, Pennsylvania, May 21 -- Pennsylvania Auditor General Timothy DeFoor issued the following news release on May 20, 2205: * * * Auditor General DeFoor Releases Audits for Volunteer Firefighters' Relief Associations in 28 Counties HARRISBURG - Auditor General Timothy DeFoor today announced the release of audit reports for 47 volunteer firefighters' relief associations (VFRAs) in Adams, Allegheny, Beaver, Berks, Blair, Bucks, Butler, Cambria, Centre, Dauphin, Delaware, Elk, Erie, Fayet more PR

WILMINGTON, Delaware, May 19 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inf more PR